"Its US subsidiary, Promius Pharma, LLC, US, launched Sernivo Spray, 0.05 per cent from the US Food and Drug Administration (FDA). Sernivo Spray, a prescription topical steroid... Indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older," the company said in a BSE filing.
In February, the company had received USFDA approval to market Sernivo spray.
"This is another significant milestone for Promius Pharma... In the dermatology space, we are committed to developing innovative treatment options," Raghav Chari, Executive Vice President of Proprietary Products and President of Promius Pharma, Dr Reddys, said.